期刊文献+

不同输注途径移植骨髓间充质干细胞对阿霉素肾病大鼠疗效初探 被引量:11

The Influence of Different Infusion Methods of Bone Marrow Mesenchymal Stem Cells in Adriamycin Nephropathy Rat Model
下载PDF
导出
摘要 目的探索骨髓间充质干细胞(BMSCs)经不同输注方式移植入阿霉素慢性肾病大鼠体内对肾损伤的影响。方法SD大鼠左侧肾切除后以2.5 mg/kg剂量给大鼠尾静脉注射阿霉素,1次/周,连续2次,慢性肾病模型成功后,将成模大鼠36只随机均分为3组:阿霉素慢性肾病对照(ADR)组、干细胞经肾动脉移植(M-A)组、干细胞经外周静脉移植(M-V)组,另选12只正常大鼠设正常对照(N)组。BMSCs经体外培养后,以2×106个/mL经肾动脉注射到M-A组大鼠体内,2×106个/mL经尾静脉注射到M-V组大鼠体内,2周后再次同样方法注射等量BMSCs。检测移植当周、移植后1周、2周大鼠血尿素氮、血肌酐、24 h尿蛋白、24 h尿微量蛋白,末次注射干细胞后第1周于激光聚焦显微镜下观察大鼠肾脏病理和干细胞在肾脏内分布情况。结果M-A组、M-V组和ADR组在各观察时点血尿素氮、血肌酐、24 h尿蛋白总量、24 h尿微量蛋白均明显高于N组(P<0.01)。移植后1、2周M-A组的24 h尿微量蛋白低于ADR组(P<0.01),且M-A组的血肌酐较ADR组和M-V组均降低(P<0.01)。移植后1周,M-A组24 h尿蛋白、24 h尿微量蛋白明显低于M-V组(P<0.01);但2周时尿蛋白和微量蛋白与M-V组的差异无统计学意义。结论BMSCs移植可以改善阿霉素慢性肾病的肾损伤情况,在BMSCs移植后一段时间,BMSCs经肾动脉移植的效果优于经外周静脉移植。 Objective To investigate the effectiveness of bone marrow mesenchymal stem cell (MSC) and different transplantation methods of MSC on adriamycin (ADR) model of nephropathy in rats. Methods The ADR model of nephrop-athy was induced by left nephrectomy plus injection of ADR (2.5 mg/kg) in Sprague-Dawley (SD) rats, once a week for two weeks. The model rats with nephropathy were randomly divided into three groups: adriamycin nephropathic model control group (ADR, n=12), MSCs transplantation through right renal artery group (M-A, n=12) and MSCs transplantation through peripheral veins group (M-V, n=12). Another 12 SD rats were served as normal controls (N, n=12). MSCs were cultured, transplanted via right renal artery (2×106/mL) to rats in M-A group, and were transplanted via peripheral veins 2×106/mL) to rats in M-V group. The same procedure was repeated in two weeks. The blood urea nitrogen, serum creatinine, 24 h urine protein and 24 h uromicroprotein were detected before transplantation and in one and two weeks after the second transplanta-tion. The renal morphology and labeled cells were examined in the kidney one week after the second transplantation. Results The values of blood urea nitrogen, serum creatinine, 24 h urine protein and 24 h uromicroprotein were significant-ly higher in M-A group, M-V group and ADR group than those of N group (P〈0.01). The level of 24 h uromicroprotein was significantly lower before the second transplantation in M-A group than that of ADR group (P〈0.01). The serum level of cre-atinine was significantly decreased in M-A group than that of ADR group and M-V group (P〈0.01). The levels of 24 h urine protein and 24 h uromicroprotein were significantly lower after one week transplantation in M-A group than those of M-V group (P〈0.01). The serum level of creatinine was significantly lower two weeks after the second transplantation in M-A group than that of ADR group and M-V group (P〈0.01), but no significant differences in the levels of urine protein and uro-microprotein between M-A group and M-V group. Conclusion Transplantation of MSCs can alleviate renal damage of&nbsp;chronic ADR-induced nephropathy, which is more effective in rats with MSCs transplantation via renal artery than that in rats with MSCs transplantation via peripheral vein.
出处 《天津医药》 CAS 北大核心 2013年第12期1180-1183,I0005,共5页 Tianjin Medical Journal
基金 云南省科技厅基金资助项目(项目编号:2012FB045)
关键词 肾病 间质干细胞 骨髓移植 间质干细胞移植 疾病模型 动物 大鼠 Sprague-Dawley 阿霉素 nephrosis mesenchymal stem cells bone marrow transplantation mesenchymal stem cell transplantation dis-ease models,animal rats,Sprague-Dawley adriamycin-induced nephropathy
  • 相关文献

参考文献11

  • 1Spaeth E, Klopp A, Dembinski J, et al. Inflammation and tumor mi-croenvironments :defining the migratory itinerary of mesenchymalstem cells[J]. Gene Ther, 2008, 15(10):730-738.
  • 2林楚伟,周胜华,戴海鹰,邓平,尹芝兰,关贤颂,夏欣.转化生长因子β1在大鼠骨髓间充质干细胞移植修复梗死心肌中的作用[J].中国组织工程研究,2012,16(27):5039-5045. 被引量:5
  • 3Yuan L, Wu MJ, Sun HY, et al. VEGF-modified human embryonicmesenchymal stem cell implantation enhances protection againstcisplatin-induced acute kidney injury[J]. Am J Physiol Renal Physi-ol’2011’300(l):F207-218.
  • 4刘韵璐,廖志航,陈东辉,罗雅琪,王愿,郭文,周黎琴.两种造模方法致大鼠实验性肾病模型的肾功能及病理变化比较[J].中药药理与临床,2011,27(3):117-120. 被引量:9
  • 5覃小华,尚希福.骨髓间充质干细胞横向分化及临床应用研究进展[J].医学综述,2009,15(1):38-40. 被引量:5
  • 6Choi S,Park M, Kim J, et al. The role of mesenchymal stem cells inthe functional improvement of chronic renal failure[J]. Stem CellsDev, 2009,18(3):521-529.
  • 7Semedo P, Correa-Costa M, Antonio Cenedeze M, et al. Mesenchy-mal stem cells attenuate renal fibrosis through immune modulationand remodeling properties in a rat remnant kidney model[J]. StemCells, 2009,27(12):3063-3073.
  • 8Cavaglieri RC, Martini D, Sogayar MC, et al. Mesenchymal stemcells delivered at the subcapsule of the kidney ameliorate renal dis-ease in the rat remnant kidney model[J]. Transplant Proc, 2009,41(3):947-951.
  • 9Zonta S, De Martino M, Bedino G, et al. Which is the most suitableand effective route of administration for mesenchymal stem cell-based immunomodulation therapy in experimental kidney transplan-tation: endovenous or arterial[J]? Transplant Proc,2010, 42(4):1336-1340.
  • 10Yoo JH, Park C, Jung DI, et al. In vivo cell tracking of canine allo-genic mesenchymal stem cells administration via renal arterial cath-eterization and physiopathological effects on the kidney in twohealthy dogs[J]. J Vet Med Sci, 2011,73(2):269-274.

二级参考文献32

共引文献22

同被引文献95

引证文献11

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部